Manila Times Business
Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism (DACRA) with GLP-1, GIP and Glucagon (Triple-G) Receptor Partial Agonism
STAMFORD, Conn., June 05, 2026 (GLOBE NEWSWIRE) -- Oban BioPharma today announced that preclinical data for OBT-676, a lead small-molecule candidate for the treatment of obesity and type 2 diabetes, has been selected for a late-breaking presentation at the upcoming American Diabetes Association (ADA) 86th Scientific Sessions being held from June 5th-8th in New Orleans, LA. The study characterizes OBT-676 as a new molecular entity that achieves potent full agonism at the amylin and calcitonin rec
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Meet Rhem: The AI Home Robot That Measures Your Family's Health and Acts On It
1h ago
DITO launches BizBayani Awards to empower MSMEs
1h ago
SHARE3DCAM Launches AI Engine Algorithm Upgrade in SHARE PointClouds Studio V2.5.0, Advancing the Complete Scan-to-Deliverable Workflow for AEC and Renovation Professionals
1h ago
Citing national security, Trump Justice Dept defends White House ballroom project
1h ago